Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children
- VernacularTitle:儿童罕见病多学科诊疗的药学服务模式探索
- Author:
Liang HUANG
1
,
2
,
3
;
Qiqiong WANG
1
,
2
;
Li CHEN
1
,
2
;
Dan YU
2
,
4
;
Jin WU
2
,
4
;
Yunzhu LIN
1
,
2
;
Linan ZENG
1
,
2
;
Zhijun JIA
1
,
2
,
3
;
Guo CHENG
2
,
4
,
5
;
Lingli ZHANG
1
Author Information
1. Dept. of Pharmacy/Evidence-Based Pharmacy Center/NMPA Key Laboratory for Technical Research on Drug Products in vitro and in vivo Correlation，West China Second University Hospital，Sichuan University，Chengdu 610041，China
2. Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education，Chengdu 610041，China
3. West China School of Pharmacy，Sichuan University，Chengdu 610041，China
4. Dept. of Pediatrics，West China Second Hospital，Sichuan University，Chengdu 610041，China
5. Laboratory of Molecular Translational Medicine，Center for Translational Medicine，Sichuan University，Chengdu 610041，China
- Publication Type:Journal Article
- Keywords:
children;
rare diseases;
multidisciplinary team diagnosis and treatment;
clinical pharmacists;
pharmaceutical service
- From:
China Pharmacy
2023;34(8):1000-1004
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the pharmaceutical service model in multidisciplinary diagnosis and treatment （MDT） of rare diseases in children. METHODS Clinical pharmacists of West China Second University Hospital （hereinafter referred to as “our hospital”） participated in the process of MDT of children’s rare diseases. Clinical pharmacists took part in the entire diagnosis and treatment process of children and established the MDT pharmaceutical service model of children’s rare diseases by formulating drug treatment plans based on evidence-based practice， improving the accessibility of drugs， pharmaceutical monitoring and drug treatment management. RESULTS From January 2021 to April 2022， clinical pharmacists of our hospital had participated in a total of 39 cases of rare diseases MDT in children， including 21 hospitalized children with rare diseases and 18 outpatient com children with rare diseases， involving a total of 23 rare diseases. Clinical pharmacists completed 45 pharmaceutical zhanglingli@scu.edu.cn rounds and 26 pharmaceutical consultations for rare diseases inpatients， 25 outpatients’ MDT and 5 pharmaceutical outpatient service for outpatients with rare diseases， 38 medication educations for inpatients and outpatients with rare diseases and 25 follow-up services for out-of-hospital patients. There were 24 cases （61.54%） of off-label drug use， involving 13 rare diseases and 16 therapeutic drugs， among which off-label drug use registration of 11 drugs had been completed or was in progress. The temporary purchase evaluations of 3 drugs had been completed； 268 cases of medical insurance drug and high-value drug prescription had been reviewed. CONCLUSIONS Our hospital have primarily established a loop pharmaceutical service model of MDT for children with rare diseases， which covers inpatients and outpatients. The model improves the availability and standardization of clinical application of therapeutic drugs， and diagnosis and treatment level for children with rare diseases in our hospital.
